Surrozen develops antibody-based therapies that target the Wnt pathway, with a focus on eye diseases. SRZN reports earnings on Fri, Nov 6, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | HC Wainwright & Co. | Target raised | Buy | |
| Aug 10 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How SRZN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in SRZN in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SRZN is in one of them and how their past SRZN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SRZN in an article yet. Here's the latest on the wider market.
About Surrozen
Surrozen is a biotechnology company based in South San Francisco, California. It develops antibody-based drug candidates that act on the Wnt pathway, a signaling system involved in tissue repair. Its main focus is eye disease, with candidates in development for diabetic macular edema and the wet form of macular degeneration, conditions treated by eye specialists. The company also has a development agreement with Boehringer Ingelheim for a related candidate.
- Headquarters
- South San Francisco, CA